For Pharmaceutical Companies: A Strong Partner Network in Specialty Pharma

As a pioneer and market leader in the specialty pharma sector, Medios plays a key role in shaping the future of individualized medicine and provides significant added value for the partners in its supply network.

Security of Supply Has Priority

As a proactive solutions provider in the field of specialized ready-to-use medicinal products, Medios makes a decisive contribution to patients’ security of supply.

Patient-Specific Therapies in GMP Quality

At our six manufacturing sites we compound ready-to-use, patient-specific therapies from approved medicinal products.

Medios is part of patient care

Expertise and Commitment

Medios was founded in Berlin in 2015 with the aim of developing innovative solutions and intelligent services across a range of indications to ensure a reliable supply of specialty pharma medicinal products to patients everywhere. 

Today we are the German market leader in the specialty pharma segment, with six facilities for the GMP-compounding of patient-specific therapies, four distribution sites, and our own blister packaging center. Our team of more than 500 employees generated revenues of €1.8 billion in 2023. 

As the largest supplier of medicinal products and compounder of patient-specific therapies in Germany, Medios has built a highly functional, nationwide supply network together with more than 700 medical specialists, some 800 pharmacies, and pharmaceutical companies. We cover a wide range of complex therapeutic areas: oncology, ophthalmology, autoimmune diseases, neurology, infectious diseases, and hemophilia. The network guarantees optimal security of supply nationwide and generates valuable synergies for all partners involved.

Physicians, pharmacies, and hospitals can rely on the delivery of specialty pharmaceuticals in the highest quality to their patients within 60 minutes. This gives pharmacies and clinics greater plannability, improves their service, and means they get immediate support in an emergency

»The supply network opens attractive revenue opportunities for pharmaceutical companies and provides excellent contacts to their target groups as well as first-class sales potential, also for new products.«

Security of Supply Has Priority

As a proactive solutions provider in the field of specialized ready-to-use medicinal products, Medios makes a decisive contribution to patients’ security of supply: with regional sites and maximum deliverability, excellent logistics and supply services for industry partners, comprehensive storage and handling expertise, and supplies of emergency medication

We advise our partners on all logistics and business matters with the support of our own team of sales consultants. We are also happy to help with any pharmaceutical questions and pass them on within our open network, where our partners support one another and share best practices. They all profit from the transfer of experience and knowledge within the network, which is further enabled by our varied range of specialty pharma events.

Close cooperation between all key players, including representatives of health insurers and policymakers, promotes a partnership intelligence that in turn generates new ideas, individualized solutions, and efficient processes.

Patient-Specific Therapies in GMP Quality

 

At our six manufacturing sites we compound ready-to-use, patient-specific therapies from approved medicinal products:

  • Cytostatic preparations
  • Antibody solutions
  • Parenteral nutrient solutions
  • Antibiotics
  • Ophthalmic medication
  • Investigational medicinal products
  • Other parenteral products
  • Pain therapy medication

We strictly apply the Good Manufacturing Practice (GMP) guidelines in our cutting-edge cleanroom laboratories with H2O2 locks. Our decentralized compounding and optimized utilization of plant capacities make our operations highly efficient in terms of time and costs. Our offering even includes patient-specific blistering and fully transparent documentation of all compounding stages. With mediosconnect – our digital order and invoicing portal – we simplify cooperation with medical specialists, health insurers, and pharmacies and ensure additional safety by putting every prescription through an extra plausibility check. In 2023, we compounded a total of 400,000 patient-specific therapies.

Our market-leading competence in specialty pharma, the highest compliance standards, and our emergency hotline make us a popular partner for hospital supplies and clinical trials as well. We have a wide range of permits to compound both sterile and non-sterile investigational medicinal products, from a batch size of one through to bulk deliveries. Employees with first-class training, certified quality management, and temperature-controlled storage and supply from –80 °C to +25 °C (–112 °F to 77 °F) guarantee highest quality and safety standards with the greatest flexibility. 

Rigorously Sustainable

Medios is a strong advocate of greater sustainability in the pharma industry.

Quality is the best foundation for efficient processes: at Medios we apply an outstanding quality management system to keep our complaints ratio at a consistently low level of 0.2 %, and thereby ensure economic use of resources. Other targeted activities significantly reduce our ecological footprint. Our communications are almost exclusively digital, and we have set up our entire production and logistics system with the aim of minimizing our carbon emissions. Order dispatching and shipping is also optimized accordingly. Our sustainability promise further includes highly transparent communications, for example regarding flow of goods.

As a joint stock corporation, we are subject to particular compliance requirements. We take compliance with legislation, regulations, and ethical standards seriously and always strive to ensure that our working relationships with customers and partners are defined by mutual trust, appreciation, fairness, and respect. Our Code of Conduct lays down clear principles for our actions and defines how we comply with all applicable rules and meet our own standards for collaborative partnership that forms the basis for our company’s long-term success.

Individualized Medicine
Is the Key to Success

As mass medicine moves towards individualized medicine, specialty pharma medicinal products are becoming increasingly important. Our vision is to enable the most innovative tailored pharmacotherapies for everybody.

 

To this end we are creating a Europe-wide platform together with pharmacies, medical specialists, and pharmaceutical companies to bring the most innovative pharmacotherapies to where they are needed. 

As we move forward, we intend to exploit all market opportunities for further growth: we are strengthening our core business in Germany, expanding compounding capacity in Europe, and positioning ourselves as reliable partners for the development and compounding of patient-specific therapies. To this end we are creating a Europe-wide platform together with pharmacies, medical specialists, and pharmaceutical companies to bring the most innovative pharmacotherapies to where they are needed. We are continuing to realize our vision across Europe, with first locations in the Netherlands, Belgium, and Spain.

About Medios

Investors

People & Career